Literature DB >> 1587003

Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia line.

D Petroni1, P Comi, B Giglioni, A Stacchini, G Martinotti, A Guerrasio, G Saglio.   

Abstract

The T-lymphoma cell line Hut78 contains a rearranged c-myc oncogene derived from a translocation between the long arms of chromosomes 8 and 2; the event deletes the 3' end of the gene, causing the loss of the transcribed AT-rich sequence. It has recently been shown that the mutant c-myc mRNA is several-fold more stable than normal c-myc mRNA. We have assessed the tumorigenicity of the mutant c-myc allele by transfecting this gene and its normal counterpart into NIH3T3 cells, together with a neomycin resistance gene. Following selection for G-418 resistance, the cells were injected into nude mice. Tumors containing integrated c-myc arose in animals injected with cells transfected by the mutated, but not by the normal, allele. The results suggest that this rearranged c-myc bears a tumorigenic activity not observed in other naturally occurring mutated c-myc alleles and may have directly contributed to the tumorigenic event in the Hut78 cell line.

Entities:  

Mesh:

Year:  1992        PMID: 1587003     DOI: 10.1093/carcin/13.5.883

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  1 in total

1.  The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells.

Authors:  A Hajra; P P Liu; Q Wang; C A Kelley; T Stacy; R S Adelstein; N A Speck; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.